A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

As the old saying goes, “an ounce of prevention is worth a pound of cure,” and in my decades of experience in healthcare that ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

In countless reports and studies, obesity is often reduced to just a number: 42% of adults in the U.S. have obesity, ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

A new University of Michigan study shows that a strong majority of older Americans want health insurance — including Medicare — to cover weight loss medica ...

State lawmakers are considering expanding the types of obesity treatments covered by Nevada Medicaid, including approving ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Popular anti-diabetes and obesity drug Mounjaro, containing the active ingredient tirzepatide, is now available in India in a ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases in life expectancy and disease-free years while generating a ...